Devonian Announces Positive in Vivo Results of Thykamine™ on Gene Expression Associated With Fibrosis
QUEBEC CITY--(BUSINESS WIRE)--Feb 18, 2025--
Devonian Health Group Inc. (' Devonian ' or the ' Company ') ( TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, today announced positive results from a gene analysis conducted as part of in vivo study in STAM™ mouse model.
Thykamine™ was administered orally, at doses of 0.5 mg/kg, 5.0 mg/kg and 50.0 mg/kg once a day for a period of three (3) weeks.
Thykamine™ treatment was associated down regulation of key genes associated with the progression of inflammatory diseases toward fibrosis. These include inhibitory (%) effects on inflammatory-related genes and fibrosis-related genes namely:
Act2: up to 57%,
TGFβ : up to 49.3 % (p<0.05),
Ctgf: up to 44.2%,
Ccl2: up to 77.28% (p<0.005),
MMP9: up to 58.2% (p<0.005),
Timp1: up to 73.5% (p<0.0005),
Ccr2: up to 70.8% (p<0.0005),
Socs3: up to 46.7%,
SerpinF: up to 62.1% (p<0.05),
IFNγ: up to 73.1% (p<0.05.
Results will be published in a peer-reviewed scientific publication in 2025.
Fibrosis is the common and final pathological outcome of chronic inflammatory diseases. Several genes are associated with different fibrotic diseases such as eye fibrosis, heart fibrosis, hepatic fibrosis, intestinal fibrosis, lung fibrosis, pancreas fibrosis, renal fibrosis and skin fibrosis 1. Most genes involved in the overlapping fibrosis diseases 1,2,3,4,5 were downregulated following Thykamine™ treatment expanding its potential anti-fibrotic effect to several organs.
'The changes in gene expression observed following treatment with Thykamine™ provide further evidence of its potential benefit not only as anti-inflammatory medication and related diseases but may expand its potential use as antifibrotic medication for many chronic diseases in multiple organs,' said Dr. Andre P. Boulet, PhD, Chief Scientific Officer of the Company.
About Fibrosis 1,2,3,4,5
A complex physiological process, fibrosis encompasses both acute and chronic inflammatory disorders. It is characterized by an excessive buildup of fibrous connective tissue in and around damaged or inflamed tissues, which results in the production of permanent scars. In several organs, including the skin, heart, lungs, gut, liver, and kidneys, fibrosis is the final stage of chronic illness. Fibrotic tissue pathologic buildup leads to a loss of structural integrity and function, which raises morbidity and mortality.
About Thykamine™
Thykamine™, the first pharmaceutical product issued from Devonian's SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine™ and SUPREX™ platform are protected by several patents in North America, Europe and Asia.
About Devonian
Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.
Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies.
Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability 'from the seed to the pill'. Devonian is traded publicly on the TSX Venture Exchange (the 'Exchange') (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF).
References
Gu Chang, Shi X, Dang X, et al. Identification of Common Genes and Pathways in Eight Fibrosis Diseases, Frontiers in genetics, Jan 15 (11), art 627396, 2021.
Guo S, Zhang Q, Guo Y, et al. The role and therapeutic targeting of the CCL2/CCR2 signaling axis in inflammatory and fibrotic diseases. Frontiers in Immunology, Jan 09, 2025.
Kitagawa K, Wada T, Furuichi K, et al . Bloackade of CCR2 ameliorates progressive fibrosis in kidney. AJP, 165 (1), 237-246, 2004.
Ihn H. Pathogenesis of fibrosis: role of TGF-β and CTGF.
Curr Opin Rheumatol ,14(6):681-5, 2002.
Steen EH, Wang X, Balaji S, et al. The role of the anti-inflammatory Cytokine Interleukin-10 in Tissue Fibrosis. Advances In Wound Care, 9 (4); 184-198, 2019.
Cautionary Note Regarding Forward-Looking Statements
All statements, other than statements of historical fact, contained in this press release including but, not limited to those relating to the economic impact of clinical study, the efficiency of the highly anti-inflammatory potency proven and the position of the Thykamine™ as a possible first-line treatment of choice for several autoimmune conditions in the early stages of the disease and the reduced need for aggressive treatments with biologics and other immune modulators, that are associated with serious side effects and long-term negative consequences, and, generally, the above 'About Devonian' and 'About Altius' paragraphs, which essentially describes the Corporation's outlook, constitute 'forward-looking information' or 'forward-looking statements' within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release.
Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.
Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
CONTACT: Devonian Health Group Inc.
Mr. Luc Gregoire
President & CEO
Dr. Andre P. Boulet, PhD
Chairman, Chief Scientific Officer
Telephone: 1 (450) 979-2916
E-mail: [email protected] Financial Communications Inc.
Mr. Ben Ozerkevich
Telephone: (416) 644-2020 or (212) 812-7680
E-mail: [email protected]
www.renmarkfinancial.com
SOURCE: Devonian Health Group Inc.
Copyright Business Wire 2025.
PUB: 02/18/2025 08:45 AM/DISC: 02/18/2025 08:47 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Washington Post Ranks Aledade as Top Workplace for Sixth Consecutive Year
BETHESDA, Md.--(BUSINESS WIRE)--The Washington Post has recognized Aledade, the nation's largest network of independent value-based primary care, among the best companies to work for in their annual Top Workplaces rankings. "At Aledade, we have a talented and deeply committed team working across the country to make our mission a reality," said Helena Christianson, Aledade's chief people officer. Share Aledade was ranked seventh in The Washington Post's largest employer category for the District of Columbia area. Aledade earned The Washington Post's top employer ranking for the sixth consecutive year. Selection for the Post's honor is based on employee feedback gathered through an anonymous third-party survey which measured several aspects of workplace culture, including alignment, execution and connection. Headquartered in Bethesda, Maryland with more than 1,400 employees across the United States, Aledade fosters a mission-centric workplace with remote-first flexibility. More than 90% of employees believe that the company lives out its mission to make the health care system better for patients, primary care practices and society. The company's commitment to employee wellbeing is demonstrated by offerings such as 12 weeks of fully paid parental leave for all new parents, generous paid time off, a fully paid six-week sabbatical for employees after six years of service and training and development programs. "At Aledade, we have a talented and deeply committed team working across the country to make our mission a reality," said Helena Christianson, Aledade's chief people officer. "We're deeply committed to sustaining an innovative environment and proud to support each and every employee with comprehensive benefits and programming for their growth and wellbeing." This recognition by The Washington Post adds to Aledade's growing list of accolades as a top employer. In 2024, Forbes magazine ranked Aledade as the No. 3 best health care industry startup employer in the United States while USA Today ranked Aledade No. 4 in its rankings of companies with between 1,000 and 2,499 employees. Additionally, Modern Healthcare ranked Aledade as one of the 2024 Best Places to Work in Healthcare. About Aledade Aledade, a public benefit corporation, is the largest network of independent primary care in the country, helping independent practices, health centers and clinics deliver better care to their patients and thrive in value-based care. Through its proven, scalable model, which includes cutting-edge data analytics, user-friendly guided workflows, health care policy expertise, strong payer relationships and integrated care solutions, Aledade empowers physicians to succeed financially by keeping people healthy. Together with more than 2,400 practices, federally-qualified health centers and community health centers in 46 states and the District of Columbia, Aledade shares in the risk and reward across more than 200 value-based contracts representing nearly 3.0 million patient lives under management. To learn more, visit or follow on X (Twitter), Facebook or LinkedIn.
Business Wire
an hour ago
- Business Wire
Galatea Bio and Fabric Genomics Partner to Deliver Comprehensive Genetic Testing for Common Diseases
MIAMI & OAKLAND, Calif.--(BUSINESS WIRE)-- Galatea Bio and Fabric Genomics, a GeneDx company, announced today a strategic collaboration to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk scoring (PRS) to assess genetic susceptibility to common diseases. 'By leveraging Fabric Genomics' high-quality clinical gene panel interpretation to support Galatea's polygenic risk score reporting, we are enabling more personalized assessments of an individual's risk for common diseases,' said Martin Reese. The initial offering will include an inherited cardiovascular gene panel based on American Heart Association (AHA) recommendations, with additional PRS for cardiovascular related traits, including coronary arterial disease, high low-density lipoprotein (LDL), elevated triglycerides, low high-density lipoprotein (HDL), atrial fibrillation, hypertension, type 2 diabetes and hypothyroidism. A follow-up offering will integrate hereditary cancer panels with PRS for breast, colorectal, and prostate cancers. 'Galatea Bio is committed to making common genetic risk prediction more accurate for all,' said Carlos Bustamante, Ph.D., CEO & Co-Founder, Galatea Bio. 'Through our collaboration with Fabric Genomics, we're working to capture both rare and common genetic contributions to disease risk—delivering meaningful insights to individuals across the US and around the world.' This collaboration integrates Fabric Genomics' platform for clinical reporting and its expertise in clinical gene panel curation with Galatea Bio's advanced PRS algorithms. By combining these capabilities, the partnership provides both rare variant and polygenic genetic risk reporting using the Broad Clinical Lab's (BCL) Blended Genome - Exome. A key component of this collaboration is the integration of Galatea Bio's newly released individually-adjusted PRS solution, StrataRisk™ PRS, which provides genetic risk for individuals of all ancestries. This is made possible through a novel, proprietary algorithm that leverages data from the Galatea Bio Global Biobank to calibrate PRS scores against similar individuals in genomic ancestry space, ensuring equitable risk assessment across diverse populations. 'By leveraging Fabric Genomics' high-quality clinical gene panel interpretation to support Galatea's polygenic risk score reporting, we are enabling more personalized assessments of an individual's risk for common diseases,' said Martin Reese, Ph.D., President of Fabric Genomics. 'This combined approach allows us to better explain patients' results with a more accurate risk profile.' Evaluating both rare genetic disease variants and polygenic risk scores can have several advantages over reporting either of these independently. Traditional single-gene or multi-gene panel testing focuses on high-penetrance rare mutations, which capture a subset of patients with an inherited single gene disease and often results in negative or uncertain results, leaving many patients' risk unexplained. PRS, which aggregates the cumulative effect of numerous common genetic variants, can provide refined risk stratification. 'This collaboration between Fabric Genomics and Galatea Bio is enabled by our clinical Blended Genome - Exome,' said Niall Lennon, Ph.D., Chief Scientific Officer, Broad Clinical Labs. 'This is exactly the kind of application we envisioned for this cost-effective approach—one that will provide a more comprehensive view of genetic susceptibility to important common diseases.' About Fabric Genomics Fabric Genomics, a GeneDx company, is democratizing genomics-driven precision medicine. The company provides institutions with end-to-end clinical sequencing solutions that include the Fabric Enterprise software platform, assay design and validation support and the clinical interpretation services needed to scale genetic testing. At the core of this platform is a suite of sophisticated AI algorithms and data knowledge systems that turn data into expert clinical insights. Headquartered in Oakland, California, Fabric Genomics supports clinical applications across a variety of use cases including rare disease, oncology, cardiovascular, neurological and women's health. To learn more, visit and follow us on X and LinkedIn. About GeneDx At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world's largest, rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery and improve health system efficiencies. For more information, please visit and connect with us on LinkedIn, Facebook and Instagram. About Galatea Bio Galatea Bio is an innovative, venture-backed biotechnology company that strives to advance 'Precision Health at Scale for All.' Founded by pioneers in the fields of population genetics and bioinformatics, Galatea Bio leverages cutting-edge ancestry algorithms to scale the promise of precision health to global populations, while maintaining a strong commitment to ethical research. The company is headquartered in Miami Lakes, Florida. For more information, visit or follow us on X and LinkedIn. About the Broad Clinical Labs Broad Clinical Laboratories was founded in 2013 as a non-profit subsidiary of Broad Institute of MIT and Harvard to accelerate the world toward a better understanding, diagnosis and treatment of disease by pursuing projects, developing products and driving adoption of cutting edge genomics technologies and novel molecular assays. Broad Clinical Labs is a leader in translational genomics, having sequenced over 700,000 genomes in service of its mission to accelerate the understanding and diagnosis of human disease. Forward Looking Statements This press release may contain 'forward-looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words 'believe,' 'project,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'strategy,' 'future,' 'opportunity,' 'plan,' 'may,' 'should,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business combinations, plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic direction, and (v) our ability to enhance our artificial intelligence tools that we use in our clinical interpretation platform. The foregoing list of factors is not exhaustive. A further list and description of risks, uncertainties and other matters can be found in the 'Risk Factors' section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.
Business Wire
an hour ago
- Business Wire
LifePlus Establishes Global Clinical Validation for First-of-Its-Kind Non-Invasive Glucose and Cuffless BP Monitoring Device and Platform
SAN JOSE, Calif.--(BUSINESS WIRE)-- LifePlus, a Silicon Valley startup redefining personal health monitoring, today announced the clinical validation of LifeLeaf ®, the world's first non-invasive and cuffless wearable for continuous glucose and blood pressure tracking. The device, tested in global multi-center trials including Mayo Clinic, AMCR Clinic – San Diego, CA, Cleveland Clinic – Abu Dhabi, and Hospital Sebarang Jaya – Penang, Malaysia, delivers real-time insights without needles, invasive sensors, or cuffs, setting a new standard in scalable, preventive care management. LifeLeaf delivers clinically validated performance without the usual barriers of needles, cuffs, or cost. Share 'LifeLeaf delivers clinically validated performance without the usual barriers of needles, cuffs, or cost,' said Dr. Samuel J. Asirvatham and Dr. Narayan G. Kowlgi of Cardiovascular Medicine, Mayo Clinic, Rochester, MN. 'By making blood pressure and glucose monitoring effortless and non-invasive, it drives better patient adherence, which is crucial for managing chronic conditions like hypertension and diabetes. This scalable solution has a strong potential to transform care models globally by enabling proactive, patient-friendly disease management.' Global Dataset LifePlus has collected and analyzed over 70,000 paired multi-biomarker datapoints from more than 500 human subjects across 14 countries and 4 continents. 'This robust dataset spans a wide range of demographics—including skin tone, age, gender, and BMI—supporting the development of proprietary signal processing and highly generalizable, multi-biomarker advanced AI/ML algorithms and models,' said Ben Mbouombouo, Chief Operating Officer and Product GM of LifePlus. Clinical Results LifePlus has already conducted multiple clinical studies to demonstrate clinical validation for LifeLeaf. The most recent results of its performance vs BGM for glucose monitoring are scheduled to be showcased at the upcoming American Diabetes Association (ADA) Meeting, June 20-23, 2025. Earlier, LifeLeaf's performance vs CGM was shared at the Advanced Technology and Treatment for Diabetes (ATTD) meeting in 2023. LifePlus also published clinical validation results for blood pressure in the European Society of Hypertension meeting in 2023. Please see key highlights below: Glucose Monitoring In head-to-head studies, LifeLeaf achieved an impressive 10.8% MARD against BGM references 1 and 8.5% MARD against Dexcom G6 2 for a target dynamic range of 70-250 mg/dL, demonstrating non-invasive glucose monitoring is not only possible, but viable and scalable for real-world use. LifeLeaf attained a low 2% outlier rate 1 in blinded continuous glucose monitoring studies, comparable with invasive alternatives and underscoring its clinical reliability. Blood Pressure The cuffless blood pressure feature of LifeLeaf demonstrated impressive accuracy, with a mean difference ± standard deviation of –0.02 ± 12.5 mmHg for systolic and 0.03± 8.4 mmHg for diastolic measurements 3 for a supported dynamic range of 90/55-170/110 mmHg, validated across multiple clinical studies and real-world settings. LifeLeaf collected indefinite long-term blood pressure data as opposed to traditional ambulatory monitors, offering continuous, real-world views. LifePlus is engaged with the world's leading clinicians to establish a new longitudinal metric for assessing arterial stiffness that may better predict long-term effects of hypertension and related cardiovascular outcomes. LifeLeaf is unique because it does not require needles, cuffs, or calibration as current solutions do. It is 70% more cost-effective over a 12-month period and supports effortless daily use, which is critical for maintaining a high degree of patient adherence and delivering preventive insights. 'The results presented at ADA this year show that LifeLeaf has the potential to provide accurate data, without invasiveness or complexity,' said Dr. Timothy S. Bailey of Headlands Research – AMCR Clinic, Escondido, CA, and Dr. Jerome S. Fischer of MDRequest, San Antonio, TX. 'This kind of non-invasive monitoring is uniquely poised to improve patient adherence and enable earlier detection – two critical factors in managing chronic conditions.' Upcoming Global Clinical Trials LifePlus is now initiating additional longitudinal outcome studies for LifeLeaf across Asia, Europe, Middle East and North America, focusing on prediabetic and hypertensive populations. The goal: to prove that continuous, passive monitoring can lead to earlier interventions and measurable reductions in chronic disease incidence. 'We're incredibly encouraged by the clinical validation at world-class institutions like Mayo Clinic and Cleveland Clinic,' said Dr. Alodeep Sanyal, co-founder and CEO of LifePlus. 'It confirms what we have believed from the beginning: that non-invasive, AI-powered monitoring can be reliable and scalable. The growing global interest from healthcare providers, partners and investors reaffirms that we are at the forefront of a major shift in how we manage and prevent chronic disease.' With global spending on diabetes and cardiovascular care projected to exceed $1.5 trillion annually by 2030, the market is primed for solutions that go beyond reactive treatment. LifeLeaf is the first clinically validated solution of its kind in this space, targeting a $100B+ total addressable market. To learn more about partnership, pilot opportunities, or investment in LifeLeaf's clinically validated platform, visit Footnotes 1. Improved accuracy of a fully non-invasive continuous glucose monitor in a diverse population. T. Bailey et al. American Diabetes Association (ADA) Annual Meeting 2025. 2. The feasibility of non-invasive continuous glucose monitoring with the novel LifeLeaf wristwatch and platform. T. Bailey et al. Advanced Technology and Treatment in Diabetes (ATTD) Annual Meeting 2023. 3. The feasibility of cuffless, non-occlusive blood pressure assessments using the novel LifeLeaf wristwatch and platform. European Society of Hypertension (ESH) Annual Meeting 2023. About LifePlus LifePlus is committed to transforming how people manage and improve their health. At the heart of our innovation is LifeLeaf ®, the world's first non-invasive, effortless, wrist-worn medical device and platform for continuous, real-time remote patient monitoring. Powered by AI, this technology empowers individuals with real-time insights into their vital health parameters, enabling proactive health management, early intervention, and seamless information sharing with loved ones and care teams. Designed for the billions worldwide at risk of chronic diseases, LifePlus is redefining everyday health monitoring with comfort, continuity, and confidence.
